Jacobson Pharma Corporation Limited
HKEX:2633.HK
0.75 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,467.798 | 1,785.579 | 1,595.543 | 1,445.915 | 1,571.459 | 1,478.125 | 1,548.684 | 1,255.957 | 1,083.856 | 947.591 | 926.181 |
| Cost of Revenue
| 847.323 | 1,038.407 | 975.021 | 911.769 | 901.703 | 803.474 | 931.022 | 699.069 | 596.101 | 562.883 | 501.339 |
| Gross Profit
| 620.475 | 747.172 | 620.522 | 534.146 | 669.756 | 674.651 | 617.662 | 556.888 | 487.755 | 384.708 | 424.842 |
| Gross Profit Ratio
| 0.423 | 0.418 | 0.389 | 0.369 | 0.426 | 0.456 | 0.399 | 0.443 | 0.45 | 0.406 | 0.459 |
| Reseach & Development Expenses
| 0 | 1.166 | 6.647 | 1.78 | 3.734 | 2.6 | 2.328 | 6.342 | 5.637 | 5.727 | 3.516 |
| General & Administrative Expenses
| 203.687 | 231.347 | 213.546 | 230.174 | 206.168 | 172.253 | 172.153 | 158.641 | 159.037 | 251.871 | 267.097 |
| Selling & Marketing Expenses
| 128.69 | 196.723 | 184.087 | 177.412 | 195.286 | 168.877 | 167.075 | 145.35 | 133.807 | 105.061 | 97.974 |
| SG&A
| 325.927 | 426.904 | 390.986 | 346.862 | 370.587 | 341.13 | 339.228 | 303.991 | 292.844 | 251.871 | 267.097 |
| Other Expenses
| 0 | 30.978 | 25.576 | 10.829 | 15.045 | 5.615 | 1.675 | 0 | 0 | -1.839 | -1.818 |
| Operating Expenses
| 332.377 | 428.07 | 397.633 | 348.642 | 374.321 | 304.091 | 324.381 | 323.365 | 305.412 | 250.032 | 265.279 |
| Operating Income
| 333.126 | 319.102 | 222.889 | 185.504 | 295.435 | 339.065 | 280.109 | 254.186 | 195.957 | 138.842 | 222.917 |
| Operating Income Ratio
| 0.227 | 0.179 | 0.14 | 0.128 | 0.188 | 0.229 | 0.181 | 0.202 | 0.181 | 0.147 | 0.241 |
| Total Other Income Expenses Net
| -78.543 | -63.039 | -29.455 | -35.671 | -54.731 | -61.479 | -46.005 | -13.996 | -2.523 | -2.707 | -5.969 |
| Income Before Tax
| 254.583 | 343.315 | 235.201 | 226.096 | 262.858 | 309.106 | 251.223 | 221.246 | 182.997 | 136.135 | 216.948 |
| Income Before Tax Ratio
| 0.173 | 0.192 | 0.147 | 0.156 | 0.167 | 0.209 | 0.162 | 0.176 | 0.169 | 0.144 | 0.234 |
| Income Tax Expense
| 44.414 | 56.546 | 43.728 | 34.264 | 46.025 | 55.528 | 46.323 | 39.986 | 30.335 | 22.157 | 32.247 |
| Net Income
| 266.968 | 251.044 | 177.666 | 173.713 | 215.631 | 250.561 | 202.27 | 179.328 | 145.61 | 101.904 | 172.357 |
| Net Income Ratio
| 0.182 | 0.141 | 0.111 | 0.12 | 0.137 | 0.17 | 0.131 | 0.143 | 0.134 | 0.108 | 0.186 |
| EPS
| 0.068 | 0.13 | 0.093 | 0.091 | 0.11 | 0.13 | 0.11 | 0.11 | 0.11 | 0.078 | 0.13 |
| EPS Diluted
| 0.097 | 0.13 | 0.093 | 0.091 | 0.11 | 0.13 | 0.11 | 0.11 | 0.11 | 0.078 | 0.13 |
| EBITDA
| 429.921 | 462.037 | 415.486 | 377.205 | 484.488 | 448.34 | 409.662 | 317.223 | 263.326 | 191.787 | 266.913 |
| EBITDA Ratio
| 0.293 | 0.282 | 0.26 | 0.261 | 0.294 | 0.303 | 0.251 | 0.265 | 0.243 | 0.203 | 0.222 |